• TLX597-Tx is a PSMA^[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.
• OPTIMAL-PSMA^[2] initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification.
• Telix is developing two distinct prostate therapeutic programs, tailored to disease stage and patient condition: TLX591-Tx radio antibody-drug conjugate (rADC) in combinations with standard of care (Phase 3 in mCRPC^[3]) and TLX597-Tx intended for earlier-stage mHSPC^[4].
• Webcast today: Thursday, April 30, at 9:30 a.m. AEST (Wednesday, April 29, at 7:30 p.m. EDT). Register here: https://s1.c-conf.com/diamondpass/10053985-675tre.html

MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 International Prostate Cancer Symposium (IPCS 2026) held in Lugano, Switzerland. These findings support TLX597-Tx’s potential to deliver a treatment that overcomes quality-of-life challenges that currently limit the clinical utility of existing RLTs in earlier-stage metastatic prostate cancer.

TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA) is a novel PSMA-targeting small molecule RLT candidate with a highly favorable dosimetry profile. Significantly reduced radiation exposure to healthy organs, including the salivary glands and kidneys^[5], may lower the incidence of xerostomia (dry mouth) and renal toxicity and support better tolerability for patients. This dosimetry profile combined with higher tumor uptake compared to existing PSMA RLTs may deliver a wider therapeutic window and enable dose intensification to maximize tumor control while preserving patient quality-of-life.

OPTIMAL-PSMA is an open-label, multi-center, randomized, Phase 2 investigator-initiated trial (IIT) led by Professor Louise Emmett at St Vincent’s Hospital in Sydney, Australia. The study is evaluating the safety, dosimetry, and efficacy of an intensified dosing regimen of TLX597-Tx compared with a standard dose schedule in 120 men with advanced mCRPC, randomized on a 2:1 basis. The novel dose-intensification regimen delivers higher activity per cycle (8.5 GBq), delivered on day 1, day 3 and day 15, followed by 10-weekly dosing for three further cycles. The study aims to confirm that a dose intensified TLX597-Tx regimen will maximize the radiation dose to cancerous lesions when they are most vulnerable to damage and therefore improve overall response to treatment.

Telix believes these dosimetry data support further evaluation of TLX597-Tx in earlier-stage disease and is initiating OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive prostate cancer (mHSPC).

Principal Investigator for OPTIMAL-PSMA, Professor Louise Emmett, commented, “The goal of OPTIMAL-PSMA is to identify a dose regimen for TLX597-Tx that leads to deeper and longer responses without increasing toxicity for men with metastatic prostate cancer. We look forward to starting the Phase 2 OPTIMAL-E trial soon.”

Dr. David N. Cade, Group Chief Medical Officer at Telix, added, “These encouraging dosimetry results from OPTIMAL-PSMA, combined with earlier exploratory work^[6], are very promising and highlight TLX597-Tx’s potential to substantially increase the tumor dose while minimizing radiation to sensitive organs. For people living with earlier-stage metastatic disease, preserving quality-of-life alongside effective cancer control is mandatory. These findings support further study in mHSPC and reinforce Telix’s strategy to develop differentiated PSMA-targeting therapies, so clinicians may be able to tailor treatment choice to the patient’s disease stage and individual condition.”

TLX597-Tx is being developed alongside TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan), Telix’s lead antibody-based prostate cancer therapy candidate, currently the subject of the Phase 3 ProstACT Global^[7] trial in mCRPC, which is actively dosing patients in jurisdictions with regulatory approval and recently reported data from a safety and dosimetry lead-in^[8]. TLX591-Tx and TLX597-Tx exhibit complementary modes-of-action, suggesting the potential for distinct applications in mCRPC and mHSPC settings as part of Telix’s portfolio approach to treating prostate cancer. TLX591-Tx and TLX597-Tx have not received marketing authorization in any jurisdiction.

To view the webcast slides, click here.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

(All financial figures in United States dollars unless otherwise stated)

VANCOUVER, BC, April 30, 2026 /PRNewswire/ — OceanaGold Corporation (TSX: OGC) (NYSE: OGC) (“OceanaGold” or the “Company”) is pleased to publish its annual Sustainability Report for the year ended December 31, 2025. The report outlines OceanaGold’s sustainability performance and progress across safety, health, people and culture, community and social performance, environment, tailings management, and climate.

Gerard Bond, President and Chief Executive Officer of OceanaGold, said “In 2025 we delivered another year of meaningful progress across our sustainability priorities, while continuing to safely and responsibly deliver gold production. Embedding sustainability into how we operate is fundamental to creating and protecting value for all stakeholders. Significant improvements in our safety performance, strong community and economic contributions, and progress on decarbonization reflect the focus and commitment of our teams across the business.”

2025 Sustainability Performance Highlights

• Maintained MSCI “AA” ESG rating for the third consecutive year
• No workplace fatalities or life‑altering injuries during the year, and a 36% reduction in Total Recordable Injury Frequency Rate compared to 2024
• Supported local economies and community development, spending $110M with nearly 800 local suppliers while contributing $10M to community projects
• 38% reduction in GHG emissions¹ over the last 3 years, with an aspiration of 30% absolute reduction in Greenhouse Gas emissions by 2030
• Averaging 60% water re‑used or recycled across operating mine sites, and an updated water performance standard and site water management plans for all operating mine sites

The Company appointed David Bickerton as Executive Vice President and Chief Sustainability Officer (CSO) effective April 1, 2026. David brings a deep understanding of OceanaGold’s business, culture and Company objectives to this critical role. David joined OceanaGold in 2011 and has held a broad range of roles across the business, most recently as Asset President of Didipio Mine in the Philippines.

This year is the release of the Company’s first annual mandatory IFRS S2 Climate-related Disclosure, which provides information about the Company’s approach and annual progress of climate-related governance, strategy, risk management and metrics and targets.

Links to OceanaGold’s 2025 sustainability‑related reports

• 2025 Sustainability Report
• 2025 Climate‑related Disclosure (IFRS S2)
• 2025 Climate Transition Plan
• 2025 Sustainability Data Book
• 2025 Conflict‑Free Gold Statement
• 2025 Responsible Gold Mining Principles Conformance Report

About OceanaGold

OceanaGold is a global intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the wholly-owned Haile Gold Mine in the United States of America; the wholly-owned Macraes and Waihi operations in New Zealand; and the 80%-owned Didipio Mine in the Philippines.

For further information please contact: Investor Relations: Rebecca Henare, VP, Investor Relations, Tel: +1 604-678-4095, ir@oceanagold.com; Valerie Burns, Manager, Investor Relations, Tel: +1 604-235-0742, ir@oceanagold.com; Media Relations: Louise Burgess, VP, Communications, Tel: +1 604-403-2019, media@oceanagold.com

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/oceanagold_corporation_oceanagold_releases_2025_sustainability_r.jpg

SAN FRANCISCO, April 30, 2026 /PRNewswire/ — HyperLeap, a global innovator in logistics robotics, today announced its official entry into the North American market with a premier launch event in Santa Clara Convention Center, Silicon Valley. The company unveiled its flagship HyperSort Flexible Robotic Sorting Solution and the HyperWall Node Series, setting a new benchmark for modular, scalable, and intelligent warehouse automation.

HyperSort Solution: Build Like Blocks, Scale on Demand

The HyperSort solution is engineered as a truly modular sorting ecosystem. Each functional unit – from robotics picking arm and sorting robots to put-wall – is designed to be assembled like building blocks, enabling warehouses of any size to construct their ideal sorting line without heavy customization or facility modification.

• Modular Design: Every component is independent and interchangeable. Users can start small and add capacity module by module as order volumes grow.
• Plug-and-Play Assembly: No complex engineering required. allowing rapid deployment within 1–2 weeks.
• Flexible Scaling: Loading station, sorting robots, and robotic put-walls can be added or removed without stopping operations, perfectly adapting to seasonal spikes or business changes.
• High-Density Sorting: One sorting system can support over thousand sorting destinations, fully utilizing vertical space to maximize throughput per square foot.
• Proven Efficiency: Arc turning and dual-flap design bring higher sorting efficiency, and system sorting accuracy could achieve 99.99%. AI–powered vision for real–time jams and overflow prevention.

HyperWall Node Series: Light & Compact, Simply your warehouse order fulfillment

The HyperWall Node Series redefines workstation flexibility and ease of use.

• Lightning-Fast Setup: Each unit installs in under 10 minutes; ready to operate after basic wiring.
• Unlimited Configurability: Supports unlimited chute quantities and sizes, compatible with multiple tote dimensions.
• Intuitive Operation: Zero–threshold interface with API integration, direct order import, and an ergonomic height–adjustable screen.
• Full Traceability: Optional AI vision solution with image capture and archiving for complete dispute resolution.

As part of its global expansion, HyperLeap is pursuing early-stage cooperation with logistics integrators and channel partners across North America, targeting those seeking to reduce peak-season labor costs while maximizing flexibility and spatial efficiency. The company will showcase its solutions at ProMat 2027, inviting partners to its booth for collaboration talks and early-bird pricing.

About HyperLeap
HyperLeap delivers safe, reliable logistics robotics to global clients, driving innovation from “usable” to “trusted” automation.

Contact: sales@hyperleap.com.cn
Website: www.hyperleap.com.cn/en/

In the news release, Blockchain.com Debuts Bespoke Wealth Program For Elite Investors & High-Volume Trading Clients, issued 29-Apr-2026 by Blockchain.com over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Blockchain.com Debuts Bespoke Wealth Program For Elite Investors & High-Volume Trading Clients

Backed by Blockchain.com’s multi-billion dollar institutional BTC holdings, Blockchain Wealth provides high-net-worth clients with the liquidity and security to shift from passive exposure to active, onchain capital deployment.

By leveraging its global market experts, Blockchain Wealth is setting a new benchmark for access in crypto that reflects the standards of traditional private banking with the efficiency of blockchain-based infrastructure

LONDON, April 30, 2026 /PRNewswire/ — Blockchain.com, a global leader in cryptocurrency services for retail and institutional users, today announced the official launch of Blockchain Wealth, a premier full-service suite now available to a select global user base. Leveraging Blockchain.com’s expertise in global markets, Blockchain Wealth provides individuals with sophisticated, institutional-grade financial services. After years at the center of the crypto market and working with high-net-worth individuals, the company is moving Blockchain Wealth out of stealth mode to deliver unparalleled scale and trust to global investors.

Blockchain Wealth offers a world-class personalized experience that scales with the specific needs of the most active participants in the market. Participants in the program will also benefit from some of the highest and most competitive yield rates available in the industry. This comes at a time when institutional demand is accelerating, driven by hedge funds, corporations, and market makers seeking yield, liquidity, and value returning to onchain operations beyond BTC and ETH.

“Institutional investors on our platform have held billions of dollars in BTC for years, reflecting sustained conviction through multiple market cycles and reinforcing crypto’s role as a long term allocation, not a short term trade,” said Nic Cary, Co-Founder and Vice Chairman at Blockchain.com. “We’re now launching a bespoke program built for a new class of high-net worth participants who are moving beyond passive exposure and actively deploying capital onchain, bringing the kind of white-glove service private banks have offered their wealthiest clients for decades.”

The program provides an unrivaled level of personalization by leveraging Blockchain.com’s dedicated OTC desk to grant high-net clients direct, 24/7 individual support from the company’s seasoned market experts. Designed to be a comprehensive financial hub, the program will be the first to roll out the company’s most advanced products, including upcoming crypto-backed loans, which will offer clients flexible liquidity without requiring them to divest from their core positions. These capabilities position Blockchain Wealth as a capital-efficient solution for investors seeking to unlock liquidity while maintaining long-term exposure to digital assets.

Blockchain Wealth distinguishes itself through a robust global footprint that utilizes both onshore and offshore strategies to meet the diverse needs of investors from around the world. This expansive geographic coverage helps ensure that the program is accessible to eligible clients across the globe, including newly extended reach into Africa and Asia, making it a truly borderless wealth management solution. Operating across more than 70 jurisdictions, Blockchain.com combines global reach with a strong commitment to compliance, security, and transparency, reinforcing its position as a trusted partner for institutional capital.

As the digital asset landscape continues to mature, Blockchain.com is continuing to invest and build the infrastructure necessary for the future of programmable finance. Blockchain Wealth represents the next evolution of this mission, providing the tools, security, and individualized attention for the next generation of global wealth. As traditional finance and crypto continue to converge, Blockchain.com is uniquely positioned to serve as the bridge between these worlds, delivering the sophistication institutions expect with the innovation of onchain financial systems.

Eligible investors interested in the benefits of the Wealth program can find more information and contact the dedicated team through the official Blockchain.com platform here.

About Blockchain.com

Blockchain.com is connecting the world to the future of finance. The global leader in crypto services helping millions across the globe access cryptocurrency. Since its inception in 2011, Blockchain.com has earned the trust of more than 90 million wallets and over 40 million users, and has facilitated over $1.2 trillion in crypto transactions. Visit Blockchain.com for more information.

Media Contact: press@blockchain.com

Correction: An earlier version of this release was updated to remove a section at the end.

The article is from Shuzhi Society.

SAN FRANCISCO, April 30, 2026 /PRNewswire/ — Dreame Robot Laundry today held its global launch at DREAME NEXT in Silicon Valley, unveiling next-generation laundry care technology. The event sent a clear signal: Dreame Robot Laundry is building a laundry care ecosystem spanning washing, drying, garment care, and storage — a step further than the industry anticipated.

The launch centered on two tiers: the L9 Pro AI Inverter Washer & Dryer Set, coming to most markets in the coming months, and the concept-stage L10 Laundry Care Center and Embodied AI Laundry Robot Z1 — a progression from single product to system solution, from automation to intelligence.

L9 Pro: Intelligence from the Inside Out

At the heart of the L9 Pro lies Dreame’s proprietary AI Digital Motor, enabling dynamic sensing and autonomous adjustments that reduce user input to a minimum. MousseBloom Foam Wash pre-activates detergent into a high-density foam for deep, gentle stain removal. Oxygen Care electrolyzes water at room temperature to remove protein-based stains and bacteria, using only water —no extra chemicals needed— making it purpose-built for delicate fabrics like silk and wool. For drying, a 1%—accuracy humidity sensor works in concert with an inverter compressor to execute a precise three-stage process. The Waterfall Self-Cleaning Evaporator ensures its lint-free operation to keep the system performing as well as the day it was unboxed.

L10 Laundry Care Center: A Category Reimagined

The concept-stage L10 integrates dedicated units for daily wear, intimates, babywear, and footwear alongside a professional-grade heat-pump care closet — each on a fully independent hygiene path.

Based on internal R&D test results, the Dreame Axial Motor delivers a lifespan ten times that of conventional motors; the Twin-Rotor Inverter Compressor is 40% more compact and cuts drying time by 17%, compared with conventional compressors. Among the standout technologies, AI Lingus drew significant attention at the event — Dreame’s real-time visual detection system continuously monitors conditions inside the drum, correcting tangles, scanning for hidden moisture pockets via thermal imaging, and ensuring every drying cycle is truly complete.

Z1: Embodied AI in the Home

The concept-stage Embodied AI Laundry Robot Z1 picks up, sorts, and transfers clothing autonomously — marking the transition of the home appliance from a tool into intelligent labor seamlessly integrated into daily life.

The confidence on display at DREAME NEXT is anchored in years of rigorous R&D and relentless engineering. In Silicon Valley, Dreame Robot Laundry has shown that this is only the beginning.

Key Takeaways

• TransPerfect Legal appoints Christian Breen as Senior Director of Consulting for the Asia-Pacific region.
• Breen brings nearly two decades of experience advising on high-value construction matters across Australia and New Zealand.
• The appointment expands TransPerfect Legal’s capabilities in the construction and infrastructure sector.

NEW YORK and SYDNEY, April 30, 2026 /PRNewswire/ — TransPerfect Legal, the global leader in legal technology, AI, and advisory services, today announced the appointment of Christian Breen to its growing Asia-Pacific team. Based in Australia, Breen joins as Senior Director of Consulting, bringing expertise in construction and dispute resolution across Australia and New Zealand.

Christian Breen

Breen will take a leadership role working alongside clients and internal teams to deliver practical, technology-enabled solutions across the full dispute and investigation lifecycle. He will help organizations manage large volumes of complex and fragmented data, streamline processes, and achieve commercially focused outcomes. He will also collaborate with TransPerfect Legal’s global Construction Dispute Practice Group on high-stakes matters across the construction and infrastructure sector.

With nearly two decades of experience practicing construction and insurance law, Breen has built a reputation for advising on and resolving some of the most complex, high-value contentious matters across both private practice and in-house environments. Most recently, he served as Legal Lead ANZ for Complex Resolutions at a global infrastructure firm, where he advised on large-scale, sensitive projects from inception through resolution. His work routinely involved coordinating cross-functional teams of external counsel, internal legal stakeholders, technologists, and commercial and delivery partners across multiple jurisdictions. He held direct responsibility for resolving claims worth hundreds of millions of dollars.

“What drew me to TransPerfect Legal is its ability to combine global scale with practical, technology-driven solutions for clients,” Breen said. “Having experienced firsthand the frustrations and pressures of running complex, high-stakes disputes, I’m motivated to leverage a new generation of tools and expertise to help clients avoid and resolve those challenges.”

TransPerfect President and Co-CEO Phil Shawe remarked, “AI and other technology solutions have become essential to how legal services are delivered. Christian’s experience will give our clients a significant strategic advantage in applying those technologies, particularly in such a data-intensive industry.”

For more company news and announcements, please visit the TransPerfect News & Press Center at www.transperfect.com/about/news-and-press.

About TransPerfect Legal
TransPerfect Legal is the global leader in legal technology, AI, and advisory services for Am Law 200 and Global 100 law firms as well as corporate legal departments. With offices in more than 150 cities worldwide, solutions include forensic technology and consulting, eDiscovery and early data assessment, managed review and legal staffing, language services, deposition and trial support, and paper discovery, all offered alongside the Reef Technology ecosystem, TransPerfect Legal’s suite of proprietary applications that address the needs of legal and regulatory practitioners around the world. For more information, please visit www.transperfectlegal.com.

About TransPerfect
TransPerfect is the world’s largest provider of language and AI solutions for global business. From offices in over 150 cities on six continents, TransPerfect offers a full range of services in 200+ languages to clients worldwide. More than 6,000 global organizations employ TransPerfect’s GlobalLink^® technology to simplify the management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.

Photo – https://laotiantimes.com/wp-content/uploads/2026/04/transperfect_christian_breen.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/transperfect_legal_solutions_logo.jpg

• New presence aims to diversify FDI sources by positioning Costa Rica in one of the world’s leading decision-making hubs for global business

SINGAPORE, April 30, 2026 /PRNewswire/ — In a strategic move to place Costa Rica at the center of global investment decision-making, the Trade & Investment Promotion Agency of Costa Rica (PROCOMER) has officially opened a new Investment Promotion Office (IPO) in Singapore.

Laura López, CEO of PROCOMER.

The new office is designed to connect Costa Rica directly with companies and investment funds that are actively shaping expansion, relocation, and new operations across Asia-Pacific and beyond. It also marks a key milestone in PROCOMER’s ongoing three-year strategy to diversify foreign direct investment (FDI) sources and reduce reliance on traditional markets.

“Costa Rica is executing an ambitious, forward-looking strategy to position itself as a leading destination for high-value investment. We are not waiting for opportunities to come to us—we are actively pursuing them. Our presence in Singapore reflects that approach, establishing a strong operational foothold in Asia-Pacific to expand our global reach and engage directly with key players in global supply chains. We are competing for sophisticated industries by offering stability, world-class talent, and a reliable business environment that enables long-term growth,” said Manuel Tovar, Costa Rica’s Minister of Foreign Trade.

Singapore was a deliberate choice. With a GDP exceeding US$500 billion and a well-established role as a financial, logistics, and technology hub, the country serves as a gateway for companies managing operations across key markets such as Japan, South Korea, and Southeast Asia. From Singapore, major investment decisions are made in sectors including semiconductors, electronics, advanced manufacturing, and global services.

“Diversifying FDI sources is essential to sustaining growth, reducing exposure to global volatility, and creating more opportunities for Costa Rican talent,” said Laura López Salazar. “This office will serve as a direct bridge between Asian investors and Costa Rica’s business ecosystem, supporting companies throughout their evaluation, establishment, and expansion processes with specialized, hands-on guidance.”

According to fDi Markets, Singapore has been the origin of more than 1,700 FDI projects over the past five years (2021–2025), primarily in software and IT services, business services, and communications.

From this new base, PROCOMER will actively identify and attract investment opportunities in sectors where Costa Rica has already developed strong capabilities, including business services, advanced manufacturing—such as medical devices and semiconductors—agribusiness, and tourism infrastructure. These efforts are aligned with the evolving dynamics of global value chains.

Costa Rica’s engagement with Asia is already well established. In recent years, the country has attracted nearly 50 investment projects from Japan, including operations by companies such as Terumo Corporation, Bridgestone Corporation, and Hitachi Ltd. South Korean companies are also expanding their footprint, including SAE-A Spinning.

Beyond attracting new projects, the Singapore office will also play a key role in supporting the retention and expansion of Asian companies already operating in Costa Rica, fostering reinvestment and the development of new productive capabilities.

With this opening, Costa Rica continues to advance its strategy for a new global investment landscape-one where having a presence in key markets is essential to competing for high-value opportunities.